CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Pharma group Egetis soars after $547 million takeover offer from ANI

By Reuters News15 hours ago Updated

** Shares in Egetis Therapeutics EGTX.ST rise 11%, after the Swedish drug developer accepted a public cash offer from ANI Pharmaceuticals ANIP.O

** ANI offers a total of 5.30 billion Swedish crowns ($547 million) for all the shares in Egetis, with the price per share in the offer 12.6% above the closing price of 9.99 crowns on Wednesday

** Egetis recommends the offer to its shareholders, saying ANI is "well positioned" to accelerate the commercial launch of its Emcitate drug in the United States

** "We believe that ANI can provide the right capabilities for a successful commercialization of Emcitate", Van Lanschot Kempen analysts say

** The broker sees the offer as fair, adding it came earlier than expected

** Egetis shares rise 108% year to date

($1 = 9.6971 Swedish crowns)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.